CLSD
Clearside Biomedical, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.41
+0.00%Year over year
Reported trailing growth
- Revenue
- -56.8%
- EBITDA
- +35.4%
- EBIT
- +6.8%
- EPS
- +23.9%
- Free cash flow
- -10.9%
- Operating cash flow
- -12.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -61.7%
- EBITDA
- -5.6%
- EBIT
- -16.3%
- Net income
- -5.7%
- EPS
- +11.3%
- Free cash flow
- -28.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025